- Bay Area Times
- Posts
- Alphabet Q1 revenue +12% YoY, but company “not immune to the macro environment”
Alphabet Q1 revenue +12% YoY, but company “not immune to the macro environment”
Bay Area Times
April 25, 2025
Brought to you by:
Top stories today:
- Alphabet Q1 revenue +12% YoY, net income +46%
- Elon’s X revenue rebounds on AI, subscription growth
- Neumann’s Flow raises $100M at ~$2.5B valuation
- Yahoo ready to buy Chrome if Google ordered to divest
- Trump’s 1st 100 days marked by high executive action
0. Data and calendar
All values as of 6 AM ET / 3 AM PT, other than S&P500 and NASDAQ close (4 PM ET / 1 PM PT).
All times are ET.
Listen to our AI-generated podcast summarizing today’s newsletter (beware of hallucinations):
1. Alphabet Q1 revenue +12% YoY, but company “not immune to the macro environment”
+28% in Google Cloud revenue to $12.26B.
AI Overviews saw 1.5B users/month, up from 1B in Oct.
Trump ending de minimis loophole next month will “cause a slight headwind to our Ads business,” Google’s CBO Philipp Schindler said.
Google Services revenue in Q1 was +10% to $77.26B
+10.3% in YouTube’s ad revenue to $8.93B.
270M+ paid Google services’ subscribers overall, driven by YouTube and Google One.
Alphabet’s capital expenditure was +43% to $17.20B
Expected to invest ~$70B in capital expenditures this year, Alphabet CFO Anat Ashkenazi said.
“[M]ay fluctuate from quarter to quarter due to the impact of changes in the timing of deliveries and construction schedules,” the CFO said.
Over 365 million people worldwide suffer from osteoarthritis and there's still no cure, just painkillers and ice packs.
Cytonics’ CYT-108 is a lab-tweaked version of a natural protein (A2M) that blocks the enzymes that eat away at cartilage.
Backed by NIH grants and over 6,000 shareholders, Cytonics is now letting the public invest in its next clinical trial phase.
It’s a shot at finally treating the root cause of joint pain, not just managing it.
*Sponsored by Cytonics ($50,000 contracted). Prospective investors should review the offering materials for details, including all risk factors, before making an investment decision. Any investment involves significant risks, including the potential loss of the total investment. This advertisement is not an offer to sell or a solicitation of an offer to buy securities. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please read the offering circular before investing in Cytonics.
3. Elon’s X revenue rebounds on AI, subscription growth as ad sales stabilize
